Emergent BioSolutions has launched a military-grade auto-injection device, Emergard, which is able to manage self-injections of antidotes and other countermeasures against chemical and related threats, the company announced on Monday.
The company has stated that it will soon pursue the Food and Drug Administration's approval for the device; because it is seeking approval, the device is not marketed in the U.S. at this time.
"Emergent is excited to add the Emergard auto-injector platform to our portfolio, which allows us to supply critical medical countermeasures to militaries and countries across the globe," Adam Havey, president of the company's biodefense division, said. "Based on internal market research, we estimate the annual worldwide market for military-grade auto-injectors to be between $100 and $200 million with one major pharmaceutical company and multiple regional players in the space. We intend to build upon our broad capabilities in government contracting and commercial distribution of medical countermeasures and seize this global market opportunity to drive revenue growth."
The device has garnered preliminary interest outside of the U.S., and the company states that it will likely ship limited quantities within the last quarter of the year. The device was originally developed by Pharma Consult Ges. M.b.H of Austria, before Emergent acquired the rights to it through an exclusive worldwide license agreement.